查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401997

2030 年轉錄組學市場預測：按組件、技術、應用、最終用戶和地區進行的全球分析

Transcriptomics Market Forecasts to 2030 - Global Analysis By Component (Instruments, Services, Consumables, Software, Reagents and Other Components), Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球轉錄組學市場規模為 74 億美元，預計到 2030 年將達到 135 億美元，預測期內複合年成長率為 9.0%。

對生物體總 RNA 轉錄本的研究稱為轉錄組學，它提供有關基因表現模式、調控系統和細胞功能的寶貴資訊。轉錄組學市場包括大量研究人員，旨在研究和解釋生物體的整個轉錄組，以幫助研究人員更好地了解基因在不同情況下如何被激活或抑制，其中包括工具和技術。轉錄組學可識別疾病特異性基因表現模式和醫學中的潛在治療靶點，從而實現準確的診斷和個人化的治療策略。

2021 年7 月發表在《免疫學前沿》雜誌上的“高密度血液轉錄組學揭示了住院個體中SARS-CoV-2 感染的精確免疫特徵”。根據題為“免疫特徵的高精度免疫特徵”的研究論文，這項研究發現，條碼的序列完美匹配率平均為97.02%，平均質量得分為35.59±0.07，表明序列測定的，表明測序完成了。

對個人化醫療的興趣日益濃厚

轉錄組學對於這種範式轉變至關重要，因為它可以深入了解每個個體的基因表現模式。轉錄組分析是精準醫學的關鍵組成部分，能夠識別與疾病相關的特定 RNA 分子和基因特徵。有了這些資訊，就可以根據每個患者的分子特徵量身定做醫療干預措施，從而獲得更準確的診斷、預後和治療策略。此外，轉錄組學識別基因表現細微變化的能力可以幫助開發量身定做的治療方法、減少副作用並提高治療效果。

初期成本高

對於研究機構和實驗室來說，獲得最先進的設備、專用試劑和運算資源需要付出龐大的財務成本。轉錄組技術的取得受到這種價格障礙的限制，特別是對於資源有限的小型研究機構而言。轉錄組分析很複雜，需要複雜的工具和熟練的工人。然而，轉錄組在科學界的民主化可能會阻礙一些研究人員和機構將轉錄組涵蓋他們的研究計畫。

技術進步

RNA序列測定(RNA-Seq) 等高通量序列測定方法的不斷進步推動了轉錄組分析準確性、可擴展性和可負擔性的提高。大規模轉錄組資料集產生了有價值的見解，而日益複雜的生物資訊工具和計算技術的發展進一步增強了這些見解。此外，與蛋白質組學和基因組學等其他體學技術的整合將使人們能夠更全面地了解生物過程。

標準化和規範化問題

由於資料分析、報告和樣品製備過程缺乏標準化而導致的變異性阻礙了比較轉錄組分析結果的信心。不同的實驗方案和資料處理方法造成的差異降低了結果的有效性，並使建立普遍認可的基準變得更加困難。當結合多個研究計劃的資料或與不同大學合作時，這個問題變得非常明顯。為了提高轉錄組學研究的可靠性，需要解決標準化和規範化問題，並需要共同努力創建聯合計劃來建立標準化協議、品管程序和最佳實踐。

新冠肺炎 (COVID-19) 影響：

轉錄組研究使基因表現模式、識別潛在的治療標靶以及解釋對病毒的免疫反應成為可能。疫情帶來了挑戰，包括供應鏈中斷，阻礙了轉錄組學研究所需消耗品和試劑的供應。轉錄組學研究的重點也可能受到資金和研究重點變化的影響。

次世代定序（NGS）細分市場預計將在預測期內成為最大的細分市場

次世代定序(NGS) 徹底改變了高通量 RNA 分析，因此佔據了最大的市場佔有率。轉錄組學研究正在經歷一場 NGS 技術的革命，例如 RNA定序(RNA-Seq)，它可以對所實現的轉錄組進行同步、徹底的研究。此外，快速且準確地平行化數百萬個RNA分子序列的能力使我們能夠解釋基因表現的複雜模式，發現新的轉錄本，並提供對選擇性剪接事件的洞察。研究人員在這方面的能力已經得到提高。

預計藥物研發領域在預測期內將出現最高的複合年成長率。

藥物研究和開發的進步預示著藥物研發發現領域的盈利擴張。透過發現疾病背後的複雜分子途徑，轉錄組學提供了對基因表現模式的完整理解。這些資訊使研究人員能夠識別與特定疾病相關的基因和途徑，有助於識別和檢驗藥物研發中的目標。此外，轉錄組分析，特別是使用 RNA定序(RNA-Seq) 等技術，可以促進藥物反應、生物標記發現和安全性評估。

佔有率最大的地區：

由於支持加大投資、技術進步和科學研究的綜合因素，亞太地區佔據了最大佔有率。由於中國、印度、日本和韓國等國家越來越重視基因組學和精準醫學，因此對轉錄組技術的需求越來越大。此外，才華橫溢的研究人員的可用性以及對轉錄組學在環境科學、農業和醫學等各個行業的潛在應用的認知不斷增強也有助於市場的擴張。

複合年成長率最高的地區：

由於對精準醫學、基因組學和合作研究計劃的投資增加，預計歐洲地區將實現盈利成長。學術機構、研究機構和政府當局的大力支持促進了先進轉錄組技術和創新的採用。此外，歐洲生物技術和製藥業正在積極將轉錄組學用於藥物研發發現和市場開拓，這正在推動該地區的市場成長。

免費客製化服務：

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球轉錄組市場：依組成部分

  • 介紹
  • 裝置
  • 服務
  • 消耗品
  • 軟體
  • 試劑
  • 其他組件

第6章全球轉錄組市場：依技術分類

  • 介紹
  • 次世代定序（NGS）
  • 微陣列
  • 即時定量聚合酶鍊式反應 (Q-PCR)
  • 定序技術
  • 聚合酶鍊式反應 (PCR)
  • Sanger
  • 其他技術

第7章全球轉錄組市場：依應用分類

  • 介紹
  • 臨床診斷
  • 藥物研發
  • 診斷和疾病分析
  • 毒理基因組學
  • 其他用途

第8章全球轉錄組市場：依最終使用者分類

  • 介紹
  • 製藥和生物技術公司
  • 政府機構及學術中心
  • 受託研究機構
  • 醫院
  • 其他最終用戶

第9章全球轉錄組市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • 10X Genomics
  • Agilent Technologies Inc.
  • BGI Genomics
  • Bio-Rad Laboratories
  • Dovetail Genomics
  • F-Hoffmann La-Roche
  • Fluidigm Corporation
  • GE Healthcare Dharmacon Inc
  • General Electric Company
  • Illuminia Inc.
  • Merck & Co. Inc
  • Natera Inc
  • Pacific Biosciences of California Inc.
  • PerkinElmer Inc.
  • Promega Corporation
  • QiagenInc
  • Takara Bio Inc.
  • Thermofisher Scientific
Product Code: SMRC24517

According to Stratistics MRC, the Global Transcriptomics Market is accounted for $7.4 billion in 2023 and is expected to reach $13.5 billion by 2030 growing at a CAGR of 9.0% during the forecast period. The study of an organism's entire range of RNA transcripts is known as transcriptomics, and it offers valuable information about patterns of gene expression, regulatory systems, and cellular functions. In order to help researchers better understand how genes are activated or inhibited under various circumstances, the transcriptomics market includes tools and technologies that are intended to study and interpret an organism's whole transcriptome. Transcriptomics identifies disease-specific gene expression patterns and possible therapeutic targets in healthcare, enabling accurate diagnosis and individualized therapy strategies.

According to a research article titled "High-Density Blood Transcriptomics Reveals Precision Immune Signatures of SARS-CoV-2 Infection in Hospitalized Individuals" published in Frontiers in Immunology Journal in July 2021, the study had an average of 97.02% of sequences with perfect matching barcodes and a mean quality score of 35.59 ± 0.07, indicated that the sequencing was performed to a high level with low error.

Market Dynamics:

Driver:

Growing focus on personalized medicine

Because transcriptomics offers deep insights into each person's personal gene expression patterns, it is essential to this paradigm shift. Transcriptomic analysis, a key element of precision medicine, makes it possible to identify certain RNA molecules and gene signatures linked to diseases. With the use of this information, medical interventions can be specifically tailored to the molecular traits of each patient, resulting in more precise diagnoses, prognoses, and treatment strategies. Moreover, transcriptomics' capacity to identify small changes in gene expression aids in the creation of tailored treatments, reducing side effects, and increasing therapeutic effectiveness.

Restraint:

High initial costs

For research organizations and laboratories, acquiring cutting-edge equipment, specialty reagents, and computational resources comes at a substantial financial cost. Access to transcriptome technologies is restricted by this price barrier, especially for smaller research organizations with limited resources. The cost issue is made worse by the complex nature of the transcriptome analysis, which calls for sophisticated tools as well as skilled workers. However, the democratization of transcriptomics among the scientific community may be hampered for some researchers and institutions when attempting to include it in their research programs.

Opportunity:

Technological advancements

Improved accuracy, scalability, and affordability in transcriptomic analysis have resulted from ongoing advancements in high-throughput sequencing methods, such as RNA sequencing (RNA-Seq). Large-scale transcriptomic data sets can yield valuable insights that are further enhanced by the development of increasingly complex bioinformatics tools and computational techniques. Moreover, a more comprehensive understanding of biological processes is made possible by integration with other omics technologies, such as proteomics and genomics.

Threat:

Standardization and normalization issues

Reliability in comparing transcriptomic results is hampered by variability introduced by non-standardized processes for data analysis, reporting, and sample preparation. Inconsistencies originate from different experimental protocols and data processing methods, which reduce the validity of results and make it more difficult to establish generally recognized benchmarks. When combining data from several research projects or working with different universities, this problem is very apparent. Enhancing the reliability of transcriptome studies requires addressing standardization and normalization issues, requiring coordinated efforts to create standardized protocols, quality control procedures, and cooperative projects that establish best practices.

COVID-19 Impact:

Deciphering gene expression patterns, identifying possible treatment targets, and explaining immunological responses to the virus have all been made feasible, in large part due to transcriptomics. The pandemic has brought out difficulties, including supply chain interruptions that impede the availability of consumables and reagents necessary for transcriptomic studies. Transcriptomics study emphasis may also have been impacted by changes in funding and research priorities.

The next-generation sequencing (NGS) segment is expected to be the largest during the forecast period

Because Next-Generation Sequencing (NGS) has revolutionized high-throughput RNA analysis, it accounts for the largest share of the market. Transcriptomic research has experienced a revolution due to NGS technologies like RNA sequencing (RNA-Seq), which allow for the simultaneous and thorough investigation of accomplished transcriptomes. Furthermore, the ability to rapidly and accurately sequence millions of RNA molecules in parallel has improved researchers' ability to interpret intricate patterns of gene expression, discover new transcripts, and provide insight into alternative splicing events.

The drug discovery segment is expected to have the highest CAGR during the forecast period

Because of the advancements in pharmaceutical research and development, the drug discovery segment is predicted to see profitable expansion. Through the discovery of complex molecular pathways underlying diseases, transcriptomics offers a thorough understanding of gene expression patterns. This information helps identify and validate targets in drug discovery by enabling researchers to identify genes and pathways linked to particular illnesses. Moreover, drug reactions, biomarker discovery, and safety evaluation are made easier by transcriptomic analysis, especially when using technologies such as RNA sequencing (RNA-Seq).

Region with largest share:

Because of the confluence of elements supporting greater investment, advances in technology, and scientific research, the Asia-Pacific area accounted for the largest proportion. Transcriptomic technologies are becoming more and more in demand as a result of the increased emphasis on genomics and precision medicine in nations like China, India, Japan, and South Korea. Additionally, the market is also expanding due to the availability of highly qualified researchers and rising awareness of the potential uses of transcriptomics in a variety of industries, such as environmental science, agriculture, and healthcare.

Region with highest CAGR:

Because of the growing investments in precision medicine, genomics, and joint research projects, the European region is predicted to have profitable growth. The adoption of advanced transcriptomic techniques and technical innovation have been facilitated by substantial support from academic institutions, research organizations, and government authorities. Moreover, transcriptomics is being actively used in drug discovery and development by the European biotechnology and pharmaceutical industries, which is fueling the market's growth in the region.

Key players in the market:

Some of the key players in Transcriptomics market include 10X Genomics, Agilent Technologies Inc., BGI Genomics, Bio-Rad Laboratories, Dovetail Genomics, F-Hoffmann La-Roche, Fluidigm Corporation, GE Healthcare Dharmacon Inc, General Electric Company, Illuminia Inc., Merck & Co. Inc, Natera Inc, Pacific Biosciences of California Inc., PerkinElmer Inc., Promega Corporation, QiagenInc Takara Bio Inc. and Thermofisher Scientific.

Key Developments:

In May 2022, BioSkryb Genomics launched the Early Access Program (EAP) for ResolveOME. This unified, single-cell workflow amplifies the complete genome and full-length mRNA transcripts of the entire transcriptome from the same cell.

In January 2022, Parse Biosciences, a provider of single-cell sequencing solutions for researchers partnered with Research Instruments Pte Ltd to provide Parse's Evercode Whole Transcriptome Kits (WTKs), Cell Fixation Kits, and Nuclei Fixation Kits in Singapore and Southeast Asia.

Components Covered:

  • Instruments
  • Services
  • Consumables
  • Software
  • Reagents
  • Other Components

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Microarrays
  • Real-time Quantitative Polymerase Chain Reaction (Q-PCR)
  • Sequencing Technology
  • Polymerase Chain Reaction (PCR)
  • Sanger
  • Other Technologies

Applications Covered:

  • Clinical Diagnostics
  • Drug Discovery
  • Diagnostics and Disease Profiling
  • Toxic genomics
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Companies
  • Government Institutes and Academic Centers
  • Contract Research Organizations
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Transcriptomics Market, By Component

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Services
  • 5.4 Consumables
  • 5.5 Software
  • 5.6 Reagents
  • 5.7 Other Components

6 Global Transcriptomics Market, By Technology

  • 6.1 Introduction
  • 6.2 Next-Generation Sequencing (NGS)
  • 6.3 Microarrays
  • 6.4 Real-time Quantitative Polymerase Chain Reaction (Q-PCR)
  • 6.5 Sequencing Technology
  • 6.6 Polymerase Chain Reaction (PCR)
  • 6.7 Sanger
  • 6.8 Other Technologies

7 Global Transcriptomics Market, By Application

  • 7.1 Introduction
  • 7.2 Clinical Diagnostics
  • 7.3 Drug Discovery
  • 7.4 Diagnostics and Disease Profiling
  • 7.5 Toxicogenomics
  • 7.6 Other Applications

8 Global Transcriptomics Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical and Biotechnology Companies
  • 8.3 Government Institutes and Academic Centers
  • 8.4 Contract Research Organizations
  • 8.5 Hospitals
  • 8.6 Other End Users

9 Global Transcriptomics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 10X Genomics
  • 11.2 Agilent Technologies Inc.
  • 11.3 BGI Genomics
  • 11.4 Bio-Rad Laboratories
  • 11.5 Dovetail Genomics
  • 11.6 F-Hoffmann La-Roche
  • 11.7 Fluidigm Corporation
  • 11.8 GE Healthcare Dharmacon Inc
  • 11.9 General Electric Company
  • 11.10 Illuminia Inc.
  • 11.11 Merck & Co. Inc
  • 11.12 Natera Inc
  • 11.13 Pacific Biosciences of California Inc.
  • 11.14 PerkinElmer Inc.
  • 11.15 Promega Corporation
  • 11.16 QiagenInc
  • 11.17 Takara Bio Inc.
  • 11.18 Thermofisher Scientific

List of Tables

  • Table 1 Global Transcriptomics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Transcriptomics Market Outlook, By Component (2021-2030) ($MN)
  • Table 3 Global Transcriptomics Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 4 Global Transcriptomics Market Outlook, By Services (2021-2030) ($MN)
  • Table 5 Global Transcriptomics Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 6 Global Transcriptomics Market Outlook, By Software (2021-2030) ($MN)
  • Table 7 Global Transcriptomics Market Outlook, By Reagents (2021-2030) ($MN)
  • Table 8 Global Transcriptomics Market Outlook, By Other Components (2021-2030) ($MN)
  • Table 9 Global Transcriptomics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 10 Global Transcriptomics Market Outlook, By Next-Generation Sequencing (NGS) (2021-2030) ($MN)
  • Table 11 Global Transcriptomics Market Outlook, By Microarrays (2021-2030) ($MN)
  • Table 12 Global Transcriptomics Market Outlook, By Real-time Quantitative Polymerase Chain Reaction (Q-PCR) (2021-2030) ($MN)
  • Table 13 Global Transcriptomics Market Outlook, By Sequencing Technology (2021-2030) ($MN)
  • Table 14 Global Transcriptomics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 15 Global Transcriptomics Market Outlook, By Sanger (2021-2030) ($MN)
  • Table 16 Global Transcriptomics Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 17 Global Transcriptomics Market Outlook, By Application (2021-2030) ($MN)
  • Table 18 Global Transcriptomics Market Outlook, By Clinical Diagnostics (2021-2030) ($MN)
  • Table 19 Global Transcriptomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 20 Global Transcriptomics Market Outlook, By Diagnostics and Disease Profiling (2021-2030) ($MN)
  • Table 21 Global Transcriptomics Market Outlook, By Toxicogenomics (2021-2030) ($MN)
  • Table 22 Global Transcriptomics Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 23 Global Transcriptomics Market Outlook, By End User (2021-2030) ($MN)
  • Table 24 Global Transcriptomics Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
  • Table 25 Global Transcriptomics Market Outlook, By Government Institutes and Academic Centers (2021-2030) ($MN)
  • Table 26 Global Transcriptomics Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
  • Table 27 Global Transcriptomics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Transcriptomics Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.